The antiphospholipid syndrome is an autoimmune disorder characterized by increased levels of circulating antiphospholipid antibodies (aPL), increased thrombotic tendency, and pregnancy morbidity.
1,2 Although advances in the treatment and follow-up of individuals with positive aPL have markedly reduced the occurrence of thrombotic events, it has become increasingly recognized that accelerated atherosclerosis is an additional problem in patients with aPL, as in other rheumatic diseases.